Inhibition of PP2A by hesperetin may contribute to Akt and ERK1/2 activation status in cortical neurons

Archives of Biochemistry and Biophysics

Volumn 650, Issue , 2018, Pages 14-21

  Vauzour, David ^a   Corsini, Simone ^a   Müller, Michael ^a   Spencer, Jeremy P E ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

Brain; Flavonoids; MAP kinase; Phosphatase; Signaling pathways

Indexed keywords

BETA ACTIN; HESPERETIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; ENZYME INHIBITOR; HESPERIDIN; PHOSPHOPROTEIN PHOSPHATASE 2;

ANIMAL CELL; ARTICLE; BRAIN CELL; BRAIN CELL CULTURE; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SUBSTRATE COMPLEX; HYDROPHOBICITY; IMMUNOBLOTTING; MAPK SIGNALING; MOLECULAR DOCKING; MOUSE; NONHUMAN; PI3K/AKT SIGNALING; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; CELL CULTURE; CYTOLOGY; DRUG EFFECT; METABOLISM; MOLECULAR MODEL; NERVE CELL;

ANIMALS; CELLS, CULTURED; CEREBRAL CORTEX; ENZYME ACTIVATION; ENZYME INHIBITORS; HESPERIDIN; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MODELS, MOLECULAR; NEURONS; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 85047207516     PISSN: 00039861     EISSN: 10960384     Source Type: Journal    
DOI: 10.1016/j.abb.2018.04.020     Document Type: Article

References (83)

1. Letenneur, L., Proust-Lima, C., Le, G.A., Dartigues, J.F., Barberger-Gateau, P., Flavonoid intake and cognitive decline over a 10-year period. Am. J. Epidemiol. 165:12 (2007), 1364–1371.
2. Morris, M.C., Evans, D.A., Tangney, C.C., Bienias, J.L., Wilson, R.S., Associations of vegetable and fruit consumption with age-related cognitive change. Neurology 67:8 (2006), 1370–1376.
3. Neshatdoust, S., Saunders, C., Castle, S.M., Vauzour, D., Williams, C., Butler, L., Lovegrove, J.A., Spencer, J.P., High-flavonoid intake induces cognitive improvements linked to changes in serum brain-derived neurotrophic factor: two randomised, controlled trials. Nutr. Healthy Aging 4:1 (2016), 81–93.
4. Dai, Q., Borenstein, A.R., Wu, Y., Jackson, J.C., Larson, E.B., Fruit and vegetable juices and Alzheimer's disease: the Kame Project. Am. J. Med. 119:9 (2006), 751–759.
5. Pasinetti, G.M., Wang, J., Ho, L., Zhao, W., Dubner, L., Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment. Biochim. Biophys. Acta 1852:6 (2015), 1202–1208.
6. Checkoway, H., Powers, K., Smith-Weller, T., Franklin, G.M., Longstreth, W.T. Jr., Swanson, P.D., Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am. J. Epidemiol. 155:8 (2002), 732–738.
7. Chen, M., Wang, T., Yue, F., Li, X., Wang, P., Li, Y., Chan, P., Yu, S., Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral alpha-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys. Neuroscience 286 (2015), 383–392.
8. Gonzalez-Sarrias, A., Nunez-Sanchez, M.A., Tomas-Barberan, F.A., Espin, J.C., Neuroprotective effects of bioavailable polyphenol-derived metabolites against oxidative stress-induced cytotoxicity in human neuroblastoma SH-SY5Y cells. J. Agric. Food Chem. 65:4 (2017), 752–758.
9. Wang, M., Li, Y.J., Ding, Y., Zhang, H.N., Sun, T., Zhang, K., Yang, L., Guo, Y.Y., Liu, S.B., Zhao, M.G., Wu, Y.M., Silibinin prevents autophagic cell death upon oxidative stress in cortical neurons and cerebral ischemia-reperfusion injury. Mol. Neurobiol. 53:2 (2016), 932–943.
10. Telerman, A., Ofir, R., Kashman, Y., Elmann, A., 3,5,4 ‘-trihydroxy-6,7,3 ‘-trimethoxyflavone protects against beta amyloid-induced neurotoxicity through antioxidative activity and interference with cell signaling. Bmc Complem. Altern. M, 17, 2017.
11. Dal-Pan, A., Dudonne, S., Bourassa, P., Bourdoulous, M., Tremblay, C., Desjardins, Y., Calon, F., Consortium, N., Cognitive-enhancing effects of a polyphenols-rich extract from fruits without changes in neuropathology in an animal model of Alzheimer's disease. J. Alzheimers Dis. 55:1 (2017), 115–135.
12. Rendeiro, C., Vauzour, D., Kean, R.J., Butler, L.T., Rattray, M., Spencer, J.P.E., Williams, C.M., Blueberry supplementation induces spatial memory improvements and region-specific regulation of hippocampal BDNF mRNA expression in young rats. Psychopharmacology 223:3 (2012), 319–330.
13. Datla, K.P., Christidou, M., Widmer, W.W., Rooprai, H.K., Dexter, D.T., Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. Neuroreport 12:17 (2001), 3871–3875.
14. Milbury, P.E., Kalt, W., Xenobiotic metabolism and berry flavonoid transport across the blood-brain barrier. J. Agric. Food Chem. 58:7 (2010), 3950–3956.
15. Passamonti, S., Vrhovsek, U., Vanzo, A., Mattivi, F., Fast access of some grape pigments to the brain. J. Agric. Food Chem. 53:18 (2005), 7029–7034.
16. Youdim, K.A., Shukitt-Hale, B., Joseph, J.A., Flavonoids and the brain: interactions at the blood-brain barrier and their physiological effects on the central nervous system. Free Radic. Biol. Med. 37:11 (2004), 1683–1693.
17. Vauzour, D., Camprubi-Robles, M., Miquel-Kergoat, S., Andres-Lacueva, C., Banati, D., Barberger-Gateau, P., Bowman, G.L., Caberlotto, L., Clarke, R., Hogervorst, E., Kiliaan, A.J., Lucca, U., Manach, C., Minihane, A.M., Mitchell, E.S., Perneczky, R., Perry, H., Roussel, A.M., Schuermans, J., Sijben, J., Spencer, J.P., Thuret, S., van de Rest, O., Vandewoude, M., Wesnes, K., Williams, R.J., Williams, R.S., Ramirez, M., Nutrition for the ageing brain: towards evidence for an optimal diet. Ageing Res. Rev. 35 (2017), 222–240.
18. Fjell, A.M., McEvoy, L., Holland, D., Dale, A.M., Walhovd, K.B., I. Alzheimer's Disease Neuroimaging, what is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Prog. Neurobiol. 117 (2014), 20–40.
19. Rothwell, J.A., Perez-Jimenez, J., Neveu, V., Medina-Remon, A., M'Hiri, N., Garcia-Lobato, P., Manach, C., Knox, C., Eisner, R., Wishart, D.S., Scalbert, A., Phenol-Explorer 3.0: a major update of the Phenol-Explorer database to incorporate data on the effects of food processing on polyphenol content. Database, 2013, 2013, bat070.
20. Mullen, W., Archeveque, M.A., Edwards, C.A., Matsumoto, H., Crozier, A., Bioavailability and metabolism of orange juice flavanones in humans: impact of a full-fat yogurt. J. Agric. Food Chem. 56:23 (2008), 11157–11164.
21. Tomas-Navarro, M., Vallejo, F., Sentandreu, E., Navarro, J.L., Tomas-Barberan, F.A., Volunteer stratification is more relevant than technological treatment in orange juice flavanone bioavailability. J. Agric. Food Chem. 62:1 (2014), 24–27.
22. Silveira, J.Q., Cesar, T.B., Manthey, J.A., Baldwin, E.A., Bai, J., Raithore, S., Pharmacokinetics of flavanone glycosides after ingestion of single doses of fresh-squeezed orange juice versus commercially processed orange juice in healthy humans. J. Agric. Food Chem. 62:52 (2014), 12576–12584.
23. Vallejo, F., Larrosa, M., Escudero, E., Zafrilla, M.P., Cerda, B., Boza, J., Garcia-Conesa, M.T., Espin, J.C., Tomas-Barberan, F.A., Concentration and solubility of flavanones in orange beverages affect their bioavailability in humans. J. Agric. Food Chem. 58:10 (2010), 6516–6524.
24. Abd El Mohsen, M.M., Kuhnle, G., Rechner, A.R., Schroeter, H., Rose, S., Jenner, P., Rice-Evans, C.A., Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic. Biol. Med. 33:12 (2002), 1693–1702.
25. Youdim, K.A., Dobbie, M.S., Kuhnle, G., Proteggente, A.R., Abbott, N.J., Rice-Evans, C., Interaction between flavonoids and the blood-brain barrier: in vitro studies. J. Neurochem. 85:1 (2003), 180–192.
26. Mogami, S., Sadakane, C., Nahata, M., Mizuhara, Y., Yamada, C., Hattori, T., Takeda, H., CRF receptor 1 antagonism and brain distribution of active components contribute to the ameliorative effect of rikkunshito on stress-induced anorexia. Sci Rep-Uk, 6, 2016.
27. Tsai, T.H., Chen, Y.F., Determination of unbound hesperetin in rat blood and brain by microdialysis coupled to microbore liquid chromatography. J. Food Drug Anal. 8:4 (2000), 331–336.
28. Aasmundstad, T.A., Morland, J., Paulsen, R.E., Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling. J. Pharmacol. Exp. Therapeut. 275:1 (1995), 435–441.
29. Paigen, K., Mammalian beta-glucuronidase: genetics, molecular biology, and cell biology. Prog. Nucleic Acid Res. Mol. Biol. 37 (1989), 155–205.
30. O'Leary, K.A., Day, A.J., Needs, P.W., Sly, W.S., O'Brien, N.M., Williamson, G., Flavonoid glucuronides are substrates for human liver beta-glucuronidase. FEBS Lett. 503:1 (2001), 103–106.
31. Shimoi, K., Nakayama, T., Glucuronidase deconjugation in inflammation. Methods Enzymol. 400 (2005), 263–272.
32. Ishisaka, A., Kawabata, K., Miki, S., Shiba, Y., Minekawa, S., Nishikawa, T., Mukai, R., Terao, J., Kawai, Y., Mitochondrial dysfunction leads to deconjugation of quercetin glucuronides in inflammatory macrophages. PLoS One, 8(11), 2013, e80843.
33. Vauzour, D., Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects. Oxid. Med. Cell. Longev., 2012, 2012, 914273.
34. Williams, R.J., Spencer, J.P., Rice-Evans, C., Flavonoids: antioxidants or signalling molecules?. Free Radic. Biol. Med. 36:7 (2004), 838–849.
35. Bahia, P.K., Rattray, M., Williams, R.J., Dietary flavonoid (-)epicatechin stimulates phosphatidylinositol 3-kinase-dependent anti-oxidant response element activity and up-regulates glutathione in cortical astrocytes. J. Neurochem. 106:5 (2008), 2194–2204.
36. Vauzour, D., Vafeiadou, K., Rice-Evans, C., Williams, R.J., Spencer, J.P., Activation of pro-survival Akt and ERK1/2 signalling pathways underlie the anti-apoptotic effects of flavanones in cortical neurons. J. Neurochem. 103:4 (2007), 1355–1367.
37. Vafeiadou, K., Vauzour, D., Lee, H.Y., Rodriguez-Mateos, A., Williams, R.J., Spencer, J.P., The citrus flavanone naringenin inhibits inflammatory signalling in glial cells and protects against neuroinflammatory injury. Arch. Biochem. Biophys. 484:1 (2009), 100–109.
38. Hunter, T., Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 80:2 (1995), 225–236.
39. Kiss, A., Becsi, B., Kolozsvari, B., Komaromi, I., Kover, K.E., Erdodi, F., Epigallocatechin-3-gallate and penta-O-galloyl-beta-D-glucose inhibit protein phosphatase-1. FEBS J. 280:2 (2013), 612–626.
40. Stadlbauer, S., Rios, P., Ohmori, K., Suzuki, K., Kohn, M., Procyanidins negatively affect the activity of the phosphatases of regenerating liver. PLoS One, 10(7), 2015, e0134336.
41. Vauzour, D., Pinto, J.T., Cooper, A.J., Spencer, J.P., The neurotoxicity of 5-S-cysteinyldopamine is mediated by the early activation of ERK1/2 followed by the subsequent activation of ASK1/JNK1/2 pro-apoptotic signalling. Biochem. J. 463:1 (2014), 41–52.
42. Perkinton, M.S., Sihra, T.S., Williams, R.J., Ca(2+)-permeable AMPA receptors induce phosphorylation of cAMP response element-binding protein through a phosphatidylinositol 3-kinase-dependent stimulation of the mitogen-activated protein kinase signaling cascade in neurons. J. Neurosci. Offi. J. Soc. Neurosci. 19:14 (1999), 5861–5874.
43. Grosdidier, A., Zoete, V., Michielin, O., SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res. 39 (2011), W270–W277 (Web Server issue).
44. Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., Ferrin, T.E., UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem. 25:13 (2004), 1605–1612.
45. Xu, Y., Xing, Y., Chen, Y., Chao, Y., Lin, Z., Fan, E., Yu, J.W., Strack, S., Jeffrey, P.D., Shi, Y., Structure of the protein phosphatase 2A holoenzyme. Cell 127:6 (2006), 1239–1251.
46. Irwin, J.J., Shoichet, B.K., ZINC–a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45:1 (2005), 177–182.
47. Sterling, T., Irwin, J.J., ZINC 15–ligand discovery for everyone. J. Chem. Inf. Model. 55:11 (2015), 2324–2337.
48. Millward, T.A., Zolnierowicz, S., Hemmings, B.A., Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem. Sci. 24:5 (1999), 186–191.
49. Fathi, A.R., Krautheim, A., Lucke, S., Becker, K., Juergen Steinfelder, H., Nonradioactive technique to measure protein phosphatase 2A-like activity and its inhibition by drugs in cell extracts. Anal. Biochem. 310:2 (2002), 208–214.
50. Green, D.D., Yang, S.I., Mumby, M.C., Molecular cloning and sequence analysis of the catalytic subunit of bovine type 2A protein phosphatase. Proc. Natl. Acad. Sci. U.S.A. 84:14 (1987), 4880–4884.
51. Xing, Y., Xu, Y., Chen, Y., Jeffrey, P.D., Chao, Y., Lin, Z., Li, Z., Strack, S., Stock, J.B., Shi, Y., Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins. Cell 127:2 (2006), 341–353.
52. Del Rio, D., Rodriguez-Mateos, A., Spencer, J.P., Tognolini, M., Borges, G., Crozier, A., Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxidants Redox Signal. 18:14 (2013), 1818–1892.
53. Rodriguez-Mateos, A., Vauzour, D., Krueger, C.G., Shanmuganayagam, D., Reed, J., Calani, L., Mena, P., Del Rio, D., Crozier, A., Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update. Arch. Toxicol. 88:10 (2014), 1803–1853.
54. Vauzour, D., Rodriguez-Mateos, A., Corona, G., Oruna-Concha, M.J., Spencer, J.P., Polyphenols and human health: prevention of disease and mechanisms of action. Nutrients 2:11 (2010), 1106–1131.
55. Mendoza, M.C., Er, E.E., Blenis, J., The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36:6 (2011), 320–328.
56. Schroeter, H., Spencer, J.P., Rice-Evans, C., Williams, R.J., Flavonoids protect neurons from oxidized low-density-lipoprotein-induced apoptosis involving c-Jun N-terminal kinase (JNK), c-Jun and caspase-3. Biochem. J. 358:Pt 3 (2001), 547–557.
57. Schaffer, S., Halliwell, B., Do polyphenols enter the brain and does it matter? Some theoretical and practical considerations. Genes Nutr. 7:2 (2012), 99–109.
58. Williams, C.M., El Mohsen, M.A., Vauzour, D., Rendeiro, C., Butler, L.T., Ellis, J.A., Whiteman, M., Spencer, J.P., Blueberry-induced changes in spatial working memory correlate with changes in hippocampal CREB phosphorylation and brain-derived neurotrophic factor (BDNF) levels. Free Radical Biol. Med. 45:3 (2008), 295–305.
59. Janle, E.M., Lila, M.A., Grannan, M., Wood, L., Higgins, A., Yousef, G.G., Rogers, R.B., Kim, H., Jackson, G.S., Ho, L., Weaver, C.M., Pharmacokinetics and tissue distribution of 14C-labeled grape polyphenols in the periphery and the central nervous system following oral administration. J. Med. Food 13:4 (2010), 926–933.
60. Spencer, J.P., Rice-Evans, C., Williams, R.J., Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability. J. Biol. Chem. 278:37 (2003), 34783–34793.
61. Westermarck, J., Hahn, W.C., Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol. Med. 14:4 (2008), 152–160.
62. Janssens, V., Goris, J., Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 353:Pt 3 (2001), 417–439.
63. Vintonyak, V.V., Antonchick, A.P., Rauh, D., Waldmann, H., The therapeutic potential of phosphatase inhibitors. Curr. Opin. Chem. Biol. 13:3 (2009), 272–283.
64. Barford, D., Das, A.K., Egloff, M.P., The structure and mechanism of protein phosphatases: insights into catalysis and regulation. Annu. Rev. Biophys. Biomol. Struct. 27 (1998), 133–164.
65. Bialy, L., Waldmann, H., Inhibitors of protein tyrosine phosphatases: next-generation drugs?. Angew Chem. Int. Ed. Engl. 44:25 (2005), 3814–3839.
66. Kasibhatla, B., Wos, J., Peters, K.G., Targeting protein tyrosine phosphatase to enhance insulin action for the potential treatment of diabetes. Curr. Opin. Invest. Drugs 8:10 (2007), 805–813.
67. Tonks, N.K., Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 7:11 (2006), 833–846.
68. Yi, T., Lindner, D., The role and target potential of protein tyrosine phosphatases in cancer. Curr. Oncol. Rep. 10:2 (2008), 114–121.
69. Zhang, Z.Y., Protein tyrosine phosphatases: prospects for therapeutics. Curr. Opin. Chem. Biol. 5:4 (2001), 416–423.
70. Elchebly, M., Payette, P., Michaliszyn, E., Cromlish, W., Collins, S., Loy, A.L., Normandin, D., Cheng, A., Himms-Hagen, J., Chan, C.C., Ramachandran, C., Gresser, M.J., Tremblay, M.L., Kennedy, B.P., Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283:5407 (1999), 1544–1548.
71. Klaman, L.D., Boss, O., Peroni, O.D., Kim, J.K., Martino, J.L., Zabolotny, J.M., Moghal, N., Lubkin, M., Kim, Y.B., Sharpe, A.H., Stricker-Krongrad, A., Shulman, G.I., Neel, B.G., Kahn, B.B., Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell Biol. 20:15 (2000), 5479–5489.
72. Testai, L., Calderone, V., Nutraceutical value of citrus flavanones and their implications in cardiovascular disease. Nutrients, 9(5), 2017.
73. Greif, D.M., Kou, R., Michel, T., Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: evidence for crosstalk between phosphorylation sites. Biochemistry 41:52 (2002), 15845–15853.
74. Nhan, J., Panneerseelan, L., Ruan, T., Wan, X., Johnson, E., Li, Y.Y., Zhang, Q.J., Abel, E.D., Symons, J.D., PP2A activation is required for lipid-induced arterial dysfunction in mice. Faseb. J., 27, 2013.
75. Braithwaite, S.P., Voronkov, M., Stock, J.B., Mouradian, M.M., Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease. Neurochem. Int. 61:6 (2012), 899–906.
76. Hirsch, E.C., Hunot, S., Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 8:4 (2009), 382–397.
77. Sontag, J.M., Sontag, E., Protein phosphatase 2A dysfunction in Alzheimer's disease. Front. Mol. Neurosci., 7, 2014, 16.
78. Alonso, A.D., Zaidi, T., Novak, M., Barra, H.S., Grundke-Iqbal, I., Iqbal, K., Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J. Biol. Chem. 276:41 (2001), 37967–37973.
79. Arima, K., Hirai, S., Sunohara, N., Aoto, K., Izumiyama, Y., Ueda, K., Ikeda, K., Kawai, M., Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res. 843:1–2 (1999), 53–61.
80. Ross, C.A., Poirier, M.A., Protein aggregation and neurodegenerative disease. Nat. Med. 10:Suppl (2004), S10–S17.
81. Guan, K.L., Dixon, J.E., Evidence for protein-tyrosine-phosphatase catalysis proceeding via a cysteine-phosphate intermediate. J. Biol. Chem. 266:26 (1991), 17026–17030.
82. Cho, H., Krishnaraj, R., Kitas, E., Bannwarth, W., Walsh, C.T., Anderson, K.S., Isolation and structural elucidation of a novel phosphocysteine intermediate in the LAR protein tyrosine phosphatase enzymic pathway. J. Am. Chem. Soc. 114:18 (1992), 7296–7298.
83. Spencer, J.P., Kuhnle, G.G., Williams, R.J., Rice-Evans, C., Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites. Biochem. J. 372:Pt 1 (2003), 173–181.